TissueTech Appoints Dr. Frank Young Executive Vice President of Regulatory Affairs
Published: May 10, 2018
“Dr. Young’s appointment continues TissueTech’s tradition as a leader in innovation and quality,” said Amy Tseng, Chief Executive Officer of TissueTech. “He adds to our culture of science and clinical strength in the service of better medicine as we continue to develop the full potential of placental tissue to address unmet needs in healthcare.”
Dr. Young is a previous Commissioner of the U.S. Food and Drug Administration (FDA), and served as Deputy Assistant Secretary of the U.S. Department of Health and Human Services He was previously Executive Vice President of Regulatory and Clinical Affairs at Braeburn Pharmaceutical, Interim Vice President for Clinical and Regulatory Affairs of Bioventus, and has served in a leadership capacity with multiple other life sciences groups. Previous to his appointment to lead the FDA, Dr. Young was Dean of the School of Medicine and Dentistry and Vice President for Health Affairs at the University of Rochester.
While serving at the U.S. Department of Health Human Services, Dr. Young received the Surgeon General’s Award for Outstanding Integrity, and the Surgeon General’s Exemplary Service Medal from the U.S. Public Health Service. In 2015, he received the Distinguished Scientist Award from the American College of Toxicology. Dr. Young has contributed to more than 200 scientific publications in biotechnology and pathology. Dr. Young is a member of the National Academies of Science, Engineering and Medicine.
About TissueTech, Inc.
TissueTech, Inc., the parent company of AMNIOX Medical and Bio-Tissue, Inc., pioneered the development and clinical application of amniotic tissue-based products. AMNIOX Medical markets products for use in the musculoskeletal and wound care markets; Bio-Tissue markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 30 continuous years of research grants. Since the company’s inception, clinicians have performed more than 300,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform. The company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing.
For TissueTech Inc.
Source: TissueTech Inc.